scispace - formally typeset
Open AccessJournal ArticleDOI

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

Daniel Ontaneda, +3 more
- 01 Apr 2017 - 
- Vol. 389, Iss: 10076, pp 1357-1366
TLDR
The current status of therapy for progressive multiple sclerosis is summarized, prospects for the future are outlined, and effective therapies that prevent worsening, reverse damage, and restore function are outlined.
About: 
This article is published in The Lancet.The article was published on 2017-04-01 and is currently open access. It has received 221 citations till now. The article focuses on the topics: Multiple sclerosis.

read more

Citations
More filters
Journal ArticleDOI

Toll-like receptors in the pathogenesis of neuroinflammation

V. Kumar
- 15 Jul 2019 - 
TL;DR: The role of various immune cells present in the brain and their role in the pathogenesis of neuroinflammation depending on the type of TLR expressed is described and the role of TLRs in bacterial meningitis, viral encephalitis, stroke, Alzheimer's disease, Parkinson's disease (PD), and autoimmune disease including multiple sclerosis (MS) is described.
Journal ArticleDOI

Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence

Marziyeh Hajialyani, +6 more
- 12 Feb 2019 - 
TL;DR: A limited number of clinical trials showed that hesperidin-enriched dietary supplements can significantly improve cerebral blood flow, cognition, and memory performance, and further clinical trials are also required for confirming neuroprotective efficacy of this natural flavonoid and evaluating its safety profile.
Journal ArticleDOI

Multiple sclerosis and cognition: synaptic failure and network dysfunction

Massimiliano Di Filippo, +3 more
- 29 Aug 2018 - 
TL;DR: The hypothesis that, during MS, immune-mediated alterations of synapses’ ability to express long-term plastic changes may contribute to the pathogenesis of cognitive impairment by interfering with the dynamics of neuronal networks is discussed.
Journal ArticleDOI

Ocrelizumab and Other CD20 + B-Cell-Depleting Therapies in Multiple Sclerosis.

Jeffrey M. Gelfand, +2 more
- 01 Oct 2017 - 
TL;DR: Advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab are reviewed.
Journal ArticleDOI

Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis

Violaine K. Harris, +7 more
- 01 Mar 2018 - 
TL;DR: The possible reversal of disability that was observed in a subset of patients warrants a larger phase II placebo-controlled study to establish efficacy of IT MSC-NP treatment in patients with MS.
References
More filters
Journal ArticleDOI

Axonal transection in the lesions of multiple sclerosis.

Bruce D. Trapp, +5 more
- 29 Jan 1998 - 
TL;DR: Transected axons are common in the lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease.
Journal ArticleDOI

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos, +10 more
- 05 Mar 2010 - 
TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Journal ArticleDOI

Defining the clinical course of multiple sclerosis: The 2013 revisions

Fred D. Lublin, +31 more
- 15 Jul 2014 - 
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Jeffrey A. Cohen, +16 more
- 05 Mar 2010 - 
TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
Journal ArticleDOI

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

John W. Peterson, +5 more
- 01 Sep 2001 - 
TL;DR: The hypothesis that demyelination, axonal transection, dendritic tran section, and apoptotic loss of neurons in the cerebral cortex contribute to neurological dysfunction in MS patients is supported.
Related Papers (5)

Defining the clinical course of multiple sclerosis: The 2013 revisions

Fred D. Lublin, +31 more
- 15 Jul 2014 - 

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalban, +21 more
- 19 Jan 2017 - 

Immunopathology of multiple sclerosis

Calliope A. Dendrou, +3 more
- 15 Sep 2015 - 

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, +17 more
- 01 Feb 2011 - 

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

Paul Browne, +6 more
- 09 Sep 2014 - 
Frequently Asked Questions (4)
Q1. What is the underlying pathologic process in multiple sclerosis?

While development of multifocal inflammatory lesions is the underlying pathologic process in relapsing-remitting multiple sclerosis, the gradual accumulation of disability that characterizes progressive multiple sclerosis appears to result from more diffuse immune mechanisms and neurodegeneration. 

A recent review this paper summarizes the current status of therapy for progressive multiple sclerosis and outlines prospects for the future. 

effective therapies for progressive multiple sclerosis that prevent worsening, reverse damage, and restore function represent major unmet needs. 

Word count: 4179 (4000 maximum) References 85 (80 maximum) Tables: 1 (about 5 Tables/Figures) Figures: 2Page 2Multiple sclerosis is a major cause of neurologic disability, which accrues predominantly during progressive forms of the disease.